

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/34, 31/535		A1	(11) International Publication Number: WO 98/37882
			(43) International Publication Date: 3 September 1998 (03.09.98)
(21) International Application Number: PCT/US98/03485		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 26 February 1998 (26.02.98)		Published <i>With international search report.</i> <i>With amended claims.</i>	
(30) Priority Data: 08/805,646 27 February 1997 (27.02.97) US			
(71) Applicant: GUILFORD PHARMACEUTICALS INC. [US/US]; 6611 Tributary Street, Baltimore, MD 21224 (US).			
(72) Inventors: LI, Jia-Hc; 27 Warren Manor Court, Cockeysville, MD 21030 (US). HAMILTON, Gregory, S.; 6501 Frederick Road, Catonsville, MD 21228 (US). STEINER, Joseph, P.; 988 Sugar Maple Street, Hampstead, MD 21074 (US).			
(74) Agent: NATH, Gary, M.; Nath & Associates, Suite 750, 1835 K Street, N.W., Washington, DC 20006 (US).			
(54) Title: METHOD OF USING NEUROTROPHIC CARBAMATES AND UREAS			
(57) Abstract <p>This invention relates to a method of using neurotrophic low molecular weight, small molecule carbamates and ureas having an affinity for FKBP-type immunophilins, as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD OF USING NEUROTROPHIC CARBAMATES AND UREAS

BACKGROUND OF THE INVENTION5 1. Field of Invention

This invention relates to a method of using neurotrophic low molecular weight, small molecule carbamates and ureas having an affinity for FKBP-type immunophilins, as inhibitors of the enzyme activity associated with immunophilin proteins, particularly
10 peptidyl-prolyl isomerase, or rotamase, enzyme activity.

2. Description of Related Art

The term immunophilin refers to a number of proteins that serve as receptors for the principal
15 immunosuppressant drugs, cyclosporin A (CsA), FK506 and rapamycin. Known classes of immunophilins are cyclophilins and FK506 binding proteins, or FKBP's. Cyclosporin A binds to cyclophilin A while FK506 and
20 rapamycin bind to FKBP12. These immunophilin-drug complexes interface with various intracellular signal transduction systems, especially the immune and nervous systems.

Immunophilins are known to have peptidyl-prolyl
25 isomerase (PPIase), or rotamase, enzyme activity. It has been determined that rotamase enzyme activity plays a role in the catalyzation of the interconversion of the cis and trans isomers of peptide and protein substrates

for the immunophilin proteins.

Immunophilins were originally discovered and studied in the immune tissue. It was initially postulated by those skilled in the art that inhibition of the immunophilins' rotamase activity leads to inhibition of T-cell proliferation, thereby causing the immunosuppressive activity exhibited by immunosuppressant drugs, such as cyclosporin A, FK506 and rapamycin. Further study has shown that the inhibition of rotamase activity, in and of itself, does not result in immunosuppressive activity. Schreiber et al., *Science*, 1990, vol. 250, pp. 556-559. Instead, immunosuppression appears to stem from the formulation of a complex of immunosuppressant drug and immunophilin. It has been shown that immunophilin-drug complexes interact with ternary protein targets as their mode of action. Schreiber et al., *Cell*, 1991, vol. 66, pp. 807-815. In the case of FKBP-FK506 and cyclophilin-CsA, the immunophilin-drug complexes bind to the enzyme calcineurin and inhibit the T-cell receptor signalling which leads to T-cell proliferation. Similarly, the immunophilin-drug complex of FKBP-rapamycin interacts with the RAFT1/FRAP protein and inhibits the IL-2 receptor signalling.

Immunophilins have been found to be present at high concentrations in the central nervous system.

Immunophilins are enriched 10-50 times more in the central nervous system than in the immune system. Within neural tissues, immunophilins appear to influence nitric oxide synthesis, neurotransmitter release and neuronal process extension.

Surprisingly, it has been found that certain low molecular weight, small molecule carbamates and ureas with a high affinity for FKBP are potent rotamase inhibitors and exhibit excellent neurotrophic effects. Furthermore, these rotamase inhibitors are devoid of immunosuppressive activity. These findings suggest the use of rotamase inhibitors in treating various peripheral neuropathies and enhancing neuronal regrowth in the central nervous system (CNS). Studies have demonstrated that neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) may occur due to the loss, or decreased availability, of a neurotrophic substance specific for a particular population of neurons affected in the disorder.

Several neurotrophic factors affecting specific neuronal populations in the central nervous system have been identified. For example, it has been hypothesized that Alzheimer's disease results from a decrease or loss of nerve growth factor (NGF). It has thus been proposed to treat SDAT patients with exogenous nerve growth factor

or other neurotrophic proteins, such as brain derived growth factor, glial derived growth factor, ciliary neurotrophic factor and neurotrophin-3, to increase the survival of degenerating neuronal populations.

5 Clinical application of these proteins in various neurological disease states is hampered by difficulties in the delivery and bioavailability of large proteins to nervous system targets. By contrast, immunosuppressant drugs with neurotrophic activity are relatively small and
10 display excellent bioavailability and specificity. However, when administered chronically, immunosuppressant drugs exhibit a number of potentially serious side effects including nephrotoxicity, such as impairment of glomerular filtration and irreversible interstitial
15 fibrosis (Kopp et al., *J. Am. Soc. Nephrol.*, 1991, 1:162); neurological deficits, such as involuntary tremors, or non-specific cerebral angina, such as non-localized headaches (De Groen et al., *N. Engl. J. Med.*, 1987, 317:861); and vascular hypertension with
20 complications resulting therefrom (Kahan et al., *N. Engl. J. Med.*, 1989, 321:1725).

 To prevent the side effects associated with the use of the immunosuppressant compounds, the present invention provides a method of using a non-immunosuppressive
25 compound containing low molecular weight, small molecule carbamates and ureas to enhance neurite outgrowth, and to

promote neuronal growth and regeneration in various neuropathological situations where neuronal repair can be facilitated, including: peripheral nerve damage caused by physical injury or disease state such as diabetes; physical damage to the central nervous system (spinal cord and brain); brain damage associated with stroke; and neurological disorders relating to neurodegeneration, such as Parkinson's disease, SDAT (Alzheimer's disease), and amyotrophic lateral sclerosis.

10

SUMMARY OF THE INVENTION


The present invention relates to a method of using a neurotrophic low molecular weight, small molecule carbamates and ureas having an affinity for FKBP-type immunophilins. Once bound to these proteins, the neurotrophic compounds are potent inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity. A key feature of the neurotrophic compounds is that they do not exert any significant immunosuppressive activity.

15
20

Specifically, the present invention relates to a method of effecting a neuronal activity in an animal, comprising:

administering to the animal a neurotrophically effective amount of a compound of formula I:

25



or a pharmaceutically acceptable salt thereof, wherein:

A is CH₂, oxygen, NH or N-(C1-C4 alkyl);

B and D are independently Ar, hydrogen, (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl or alkynyl, (C5-C7)-cycloalkyl substituted (C1-C6)-straight or branched alkyl or (C3-C6)-straight or branched alkenyl or alkynyl, (C5-C7)-cycloalkenyl substituted (C1-C6)-straight or branched alkyl or (C3-C6)-straight or branched alkenyl or alkynyl, Ar-substituted (C1-C6)-straight or branched alkyl, Ar-substituted (C3-C6)-straight or branched alkenyl or alkynyl;

any one of the CH₂ groups of said alkyl chains may be optionally replaced by a heteroatom selected from the group consisting of O, S, SO, SO₂, and NR, wherein R is selected from the group consisting of hydrogen, (C1-C4)-straight or branched alkyl, (C3-C4)-straight or branched alkenyl or alkynyl, and (C1-C4) bridging alkyl wherein a bridge is formed between the nitrogen and a carbon atom

of said heteroatom-containing chain to form a ring, and wherein said ring is optionally fused to an Ar group;

J is selected from the group consisting of hydrogen, (C1-C6)-straight or branched alkyl, (C3-C6)-straight or branched alkenyl and $-\text{CH}_2\text{Ar}$; K is selected from the group consisting of (C1-C4)-straight or branched alkyl, $-\text{CH}_2\text{Ar}$, and cyclohexylmethyl; or J and K may be taken together to form a 5-7 membered heterocyclic ring which may contain a heteroatom selected from the group consisting of O, S, SO and SO_2 ;

Z is O or S;

Y is O or N, wherein

when Y is O, then R_1 is a lone pair and R_2 is selected from the group consisting of Ar, (C1-C6)-straight or branched alkyl, and (C3-C6)-straight or branched alkenyl or alkynyl; and

when Y is N, then R_1 and R_2 are independently selected from the group consisting of Ar, (C1-C6)-straight or branched alkyl, and (C3-C6)-straight or branched alkenyl or alkynyl; or R_1 and R_2 are taken together to form a heterocyclic 5-6 membered ring selected from the group consisting of pyrrolidine, imidazolidine, pyrazolidine, piperidine, and piperazine;

Ar is a carbocyclic aromatic group selected from the group consisting of phenyl, 1-naphthyl, 2-naphthyl, indenyl, azulenyl, fluorenyl, and anthracenyl; or a

heterocyclic aromatic group selected from the group consisting of 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, 2-pyrazoliny, 5 pyrazolidinyl, isoxazolyl, isotriazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, 1,3,4-thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, 1,3,5-trithianyl, indoliziny, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furanyl, benzo[b]thio-phenyl, 10 1H-indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H-quinoliziny, quinolinyl, 1,2,3,4-tetrahydroquinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, carbazolyl, acridinyl, 15 phenazinyl, phenothiazinyl, and phenoxazinyl;


Ar may contain one or more substituents which are independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, -SO₂H, 20 trifluoromethyl, trifluoromethoxy, (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, O-[(C1-C6)-straight or branched alkyl], O-[(C3-C4)-straight or branched alkenyl], O-benzyl, O-phenyl, 1,2-methylenedioxy, -NR₂R₃, carboxyl, N-(C1-C5-straight or branched alkyl or C3-C5-straight or branched alkenyl) 25 carboxamides, N,N-di-(C1-C5-straight or branched alkyl or C3-C5-straight or branched alkenyl) carboxamides,

5


10

13

3



II




III

or a pharmaceutically acceptable salt thereof, wherein:

Y, R₁ and R₂ are as defined in claim 1, Ar is as defined in claim 4 and w is 1 or 2.

The present invention further relates to a method of effecting a neuronal activity in an animal, comprising:
 5 administering to the animal a neurotrophically effective amount of a compound of formula III or IV:



or a pharmaceutically acceptable salt thereof, wherein:

15 Y, R₁ and R₂ are as defined in claim 1, Ar is as defined in claim 4, J is hydrogen, (C1-C6)-straight or branched alkyl or (C3-C6)-straight or branched alkenyl, and w is 1 or 2.

20 DETAILED DESCRIPTION OF THE INVENTION

Definitions

"Alkyl" means a branched or unbranched saturated hydrocarbon chain containing 1 to 6 carbon atoms, such as methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, n-pentyl, n-hexyl, and the like, unless
 25 otherwise indicated.

"Halo" means fluoro, chloro, bromo, or iodo, unless otherwise indicated.

"Pharmaceutically acceptable salt" refers to salts of the subject compounds which possess the desired pharmacological activity and which are neither biologically nor otherwise undesirable. The salts can be formed with inorganic acids such as acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, thiocyanate, tosylate and undecanoate. Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salt with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups can be quarternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates, long

chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.

5 "Phenyl" includes all possible isomeric phenyl radicals, optionally monosubstituted or multi-substituted with substituents selected from the group consisting of alkyl, alkoxy, hydroxy, halo, and haloalkyl.

10 "Treatment" covers any treatment of a disease and/or condition in an animal, particularly a human, and includes:

15 (i) preventing a disease and/or condition from occurring in a subject which may be predisposed to the disease and/or condition but has not yet been diagnosed as having it;

(ii) inhibiting the disease and/or condition, i.e., arresting its development; and


(iii) relieving the disease and/or condition, i.e., causing regression of the disease and/or condition.

20 The inventors have discovered that certain low molecular weight, small molecule carbamates and ureas have an affinity for FKBP-type immunophilins, particularly FKBP12. When the carbamates and ureas are bound to an FKBP-type immunophilin, they have been found to inhibit the prolyl-peptidyl *cis-trans* isomerase
25 activity, or rotamase, activity of the binding protein

and unexpectedly stimulate neurite growth. This activity is useful in the stimulation of damaged neurons, the promotion of neuronal regeneration, the prevention of neurodegeneration, and the treatment of several neurological disorders known to be associated with neuronal degeneration and peripheral neuropathies.

For the foregoing reasons, the present invention relates to a method of effecting a neuronal activity in an animal, comprising:

administering to the animal a neurotrophically effective amount of a compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

A is CH₂, oxygen, NH or N-(C1-C4 alkyl);

B and D are independently Ar, hydrogen, (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl or alkynyl, (C5-C7)-cycloalkyl substituted (C1-C6)-straight or branched alkyl or (C3-C6)-straight or branched alkenyl or alkynyl, (C5-C7)-cycloalkenyl substituted (C1-C6)-straight or branched alkyl or (C3-

C6)-straight or branched alkenyl or alkynyl, Ar-substituted (C1-C6)-straight or branched alkyl, Ar-substituted (C3-C6)-straight or branched alkenyl or alkynyl;

5 any one of the CH₂ groups of said alkyl chains may be optionally replaced by a heteroatom selected from the group consisting of O, S, SO, SO₂, and NR, wherein R is selected from the group consisting of hydrogen, (C1-C4)-straight or branched alkyl, (C3-C4)-straight or branched
10 alkenyl or alkynyl, and (C1-C4) bridging alkyl wherein a bridge is formed between the nitrogen and a carbon atom of said heteroatom-containing chain to form a ring, and wherein said ring is optionally fused to an Ar group;

 J is selected from the group consisting of hydrogen,
15 (C1-C6)-straight or branched alkyl, (C3-C6)-straight or branched alkenyl and -CH₂Ar; K is selected from the group consisting of (C1-C4)-straight or branched alkyl, -CH₂Ar, and cyclohexylmethyl; or J and K may be taken together to form a 5-7 membered heterocyclic ring which may contain
20 a heteroatom selected from the group consisting of O, S, SO and SO₂;

 Z is O or S;

 Y is O or N, wherein

 when Y is O, then R₁ is a lone pair and R₂ is
25 selected from the group consisting of Ar, (C1-C6)-straight or branched alkyl, and (C3-C6)-straight or

branched alkenyl or alkynyl; and

when Y is N, then R₁ and R₂ are independently selected from the group consisting of Ar, (C1-C5)-straight or branched alkyl, and (C3-C5)-straight or branched alkenyl or alkynyl; or R₁ and R₂ are taken together to form a heterocyclic 5-6 membered ring selected from the group consisting of pyrrolidine, imidazolidine, pyrazolidine, piperidine, and piperazine;

Ar is a carbocyclic aromatic group selected from the group consisting of phenyl, 1-naphthyl, 2-naphthyl, indenyl, azulenyl, fluorenyl, and anthracenyl; or a heterocyclic aromatic group selected from the group consisting of 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, 2-pyrazolinyl, pyrazolidinyl, isoxazolyl, isotriazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, 1,3,4-thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, 1,3,5-trithianyl, indolizinyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furanyl, benzo[b]thio-phenyl, 1H-indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H-quinolizinyl, quinolinyl, 1,2,3,4-tetrahydroquinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, and phenoxazinyl;

Ar may contain one or more substituents which are independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, $-SO_2R$, trifluoromethyl, trifluoromethoxy, (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, O-[(C1-C6)-straight or branched alkyl], O-[(C3-C4)-straight or branched alkenyl], O-benzyl, O-phenyl, 1,2-methylenedioxy, $-NR_1R_2$, carboxyl, N-(C1-C5-straight or branched alkyl or C3-C5-straight or branched alkenyl) carboxamides, N,N-di-(C1-C5-straight or branched alkyl or C3-C5-straight or branched alkenyl) carboxamides, morpholinyl, piperidinyl, O-X, $CH_2-(CH_2)_q-X$, $O-(CH_2)_q-X$, $(CH_2)_q-O-X$, and $CH=CH-X$;

R_1 and R_2 are independently selected from the group consisting of (C1-C6)-straight or branched alkyl, (C3-C6)-straight or branched alkenyl, hydrogen and benzyl; or R_1 and R_2 can be taken together to form a 5-6 membered heterocyclic ring;

X is selected from the group consisting of 4-methoxyphenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrazyl, quinolyl, 3,5-dimethylisoxazolyl, isoxazolyl, 2-methylthiazolyl, thiazolyl, 2-thienyl, 3-thienyl, and pyrimidyl;

q is 0-2; and

n is 0 or 1.

In a preferred embodiment, J and K are taken together to form a 5-7 membered ring.

In another preferred embodiment, at least one of B and D is independently represented by the formula -

5 $(CH_2)_r - (X) - (CH_2)_s - Ar$, wherein:

r is 1-4;

s is 0-1;

Ar is as defined in claim 1; and

each X is independently selected from the group consisting of CH_2 , O, S, SO, SO_2 , and NR, wherein R is selected from the group consisting of hydrogen, (C1-C4)-straight or branched alkyl, (C3-C4)-straight or branched alkenyl or alkynyl, and (C1-C4) bridging alkyl wherein a bridge is formed between the nitrogen atom and the Ar group.


15 In an additional preferred embodiment, Ar is selected from the group consisting of phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, indolyl, isoindolyl, quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, and 1,2,3,4-tetrahydroquinolinyl, wherein said Ar may contain one or more substituents which are independently selected from the group consisting of hydrogen, hydroxyl, nitro, trifluoromethyl, (C1-C6)-straight or branched alkyl, O-[(C1-C6)-straight or branched alkyl], halogen, SO_3H , and

20 NR_2R_3 ; and

25

R_1 and R_2 are independently selected from the group consisting of (C1-C6)-straight or branched alkyl; (C3-C6)-straight or branched alkenyl, hydrogen and benzyl; or R_1 and R_2 can be taken together to form a 5-6 membered heterocyclic ring.

The present invention also relates to a method of effecting a neuronal activity in an animal, comprising: administering to the animal a neurotrophically effective amount of a compound of formula II or III:



II


III

or a pharmaceutically acceptable salt thereof, wherein:


Y , R_1 and R_2 are as defined in claim 1, Ar is as defined in claim 4 and w is 1 or 2.

The present invention further relates to a method of effecting a neuronal activity in an animal, comprising:

administering to the animal a neurotrophically effective amount of a compound of formula III or IV:



III



IV

or a pharmaceutically acceptable salt thereof, wherein:

Y, R₁ and R₂ are as defined in claim 1, Ar is as
 10 defined in claim 4, J is hydrogen, (C1-C6)-straight or
 branched alkyl or (C3-C6)-straight or branched alkenyl,
 and w is 1 or 2.

The neuronal activity that is effected by the
 methods of the present invention may be selected from the
 15 group consisting of: stimulation of damaged neurons,
 promotion of neuronal regeneration, prevention of
 neurodegeneration and treatment of a neurological
 disorder.

Examples of a neurological disorder that is
 20 treatable by the methods of the present invention include
 without limitation: trigeminal neuralgia;
 glossopharyngeal neuralgia; Bell's Palsy; myasthenia
 gravis; muscular dystrophy; amyotrophic lateral
 sclerosis; progressive muscular atrophy; progressive
 25 bulbar inherited muscular atrophy; herniated, ruptured or
 prolapsed invertebrate disk syndromes; cervical

spondylosis; plexus disorders; thoracic outlet
destruction syndromes; peripheral neuropathies such as
those caused by lead, dapsone, ticks, porphyria, or
Guillain-Barré syndrome; Alzheimer's disease; and
5 Parkinson's disease.

The methods of the present invention are
particularly useful for treating a neurological disorder
selected from the group consisting of: peripheral
neuropathy caused by physical injury or disease state,
10 physical damage to the brain, physical damage to the
spinal cord, stroke associated with brain damage, and a
neurological disorder relating to neurodegeneration.
Examples of a neurological disorder relating to
neurodegeneration include Alzheimer's Disease,
15 Parkinson's Disease, and amyotrophic lateral sclerosis.

In the methods of the present invention, the
neurotrophic compound may be administered orally,
parenterally, by inhalation spray, topically, rectally,
nasally, buccally, vaginally or via an implanted
20 reservoir in dosage formulations containing conventional
non-toxic pharmaceutically-acceptable carriers, adjuvants
and vehicles. The term parenteral as used herein
includes subcutaneous, intravenous, intramuscular,
intraperitoneally, intrathecally, intraventricularly,
25 intrasternal and intracranial injection or infusion
techniques.

To be effective therapeutically as central nervous system targets, the neurotrophic compounds should readily penetrate the blood-brain barrier when peripherally administered. Compounds which cannot penetrate the blood-brain barrier can be effectively administered by an intraventricular route.

The neurotrophic compounds may also be administered in the form of sterile injectable preparations, for example, as sterile injectable aqueous or oleaginous suspensions. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparations may also be sterile injectable solutions or suspensions in non-toxic parenterally-acceptable diluents or solvents, for example, as solutions in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as solvents or suspending mediums. For this purpose, any bland fixed oil such as a synthetic mono- or di-glyceride may be employed. Fatty acids such as oleic acid and its glyceride derivatives, including olive oil and castor oil, especially in their polyoxyethylated versions, are useful in the preparation of injectables. These oil solutions or suspensions may

also contain long-chain alcohol diluents or dispersants.

Additionally, the neurotrophic compounds may be administered orally in the form of capsules, tablets, aqueous suspensions or solutions. Tablets may contain carriers such as lactose and corn starch, and/or lubricating agents such as magnesium stearate. Capsules may contain diluents including lactose and dried corn starch. Aqueous suspensions may contain emulsifying and suspending agents combined with the active ingredient. The oral dosage forms may further contain sweetening and/or flavoring and/or coloring agents.

The neurotrophic compounds may further be administered rectally in the form of suppositories. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at room temperature, but liquid at rectal temperature and, therefore, will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

Moreover, the neurotrophic compounds may be administered topically, especially when the conditions addressed for treatment involve areas or organs readily accessible by topical application, including neurological disorders of the eye, the skin, or the lower intestinal tract. Suitable topical formulations can be readily prepared for each of these areas.

For topical application to the eye, or ophthalmic use, the compounds can be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as a solution in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, the compounds may be formulated into ointments, such as petrolatum, for ophthalmic use.

For topical application to the skin, the compounds can be formulated into suitable ointments containing the compounds suspended or dissolved in, for example, mixtures with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, the compounds can be formulated into suitable lotions or creams containing the active compound suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

Topical application to the lower intestinal tract can be effected in a rectal suppository formulations (see above) or in suitable enema formulations.

Dosage levels on the order of about 0.1 mg to about 10,000 mg of the active ingredient compound are useful in

the treatment of the above conditions, with preferred levels of about 0.1 mg to about 1,000 mg. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

It is understood, however, that a specific dose level for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed; the age, body weight, general health, sex, and diet of the patient; the time of administration; the rate of excretion; drug combination; the severity of the particular disease being treated; and the form of administration.

The compounds can be administered with other neurotrophic agents such as neurotrophic growth factor (NGF), glial derived growth factor, brain derived growth factor, ciliary neurotrophic factor, and neurotrophin-3. The dosage level of other neurotrophic drugs will depend upon the factors previously stated and the neurotrophic effectiveness of the drug combination.


EXAMPLES

The following examples are illustrative of the present invention and are not intended to be limitations thereon. Unless otherwise specified, all percentages are

based on 100% by weight of the final compound.

The compounds used in the methods of the present invention may be readily prepared by standard techniques of organic chemistry, utilizing the general synthetic pathway depicted below. As described by Scheme I, cyclic amino acids 1 protected by suitable blocking groups P on the amino acid nitrogen may be reacted with alcohols ROH to generate esters 2. After removal of the protecting group, the free amine 3 may be reacted with a variety of isocyanates or isothiocyanates to provide the final ureas or thioureas, respectively. Alternatively, reaction of 1 with amines provides the corresponding amide compounds.


Scheme I



Isocyanates ($R^1\text{NCO}$) or isothiocyanates ($R^1\text{NCS}$) 4 may be conveniently prepared from the corresponding readily

available amines by reaction with phosgene or thiophosgene, as depicted in Scheme II.

Scheme II



10 EXAMPLE 1

Synthesis of 3-(3-pyridyl)-1-propyl (2S)-1-[(2-methylbutyl)carbamoyl]pyrrolidine-2-carboxylate (1)

15 3-(3-pyridyl)-1-propyl (2S)-N-(tert-butyloxy-carbonyl)pyrrolidine-2-carboxylate

A mixture of N-(tert-butyloxycarbonyl)-(S)-proline (3.0 g; 13.9 mmol); 3-(3-Pyridyl)-1-propanol (2.90 g; 20.9 mmol), dicyclohexylcarbodiimide (4.59 g; 22.24 mmol), camphorsulfonic acid (1.08 g; 4.63 mmol), and 4-dimethylaminopyridine (0.60 g; 4.63 mmol) in dry methylene chloride (100 mL) was stirred overnight. The reaction mixture was diluted with methylene chloride (50 mL) and water (100 mL), and the layers were separated. The organic phase was washed with water (3 x 100 mL), dried over magnesium sulfate, and concentrated, and the crude residue was purified on a silica gel column eluting

20

25

with ethyl acetate to obtain 4.60 g (95%) of the ester as
a thick oil, ^1H NMR (300 MHz, CDCl_3): δ 1.45 (s, 9H);
1.70-2.05 (m, 5H); 2.32 (m, 1H); 2.71 (t, 2H); 3.50 (m,
2H); 4.15 (m, 2H); 4.18 (m, 1H); 7.24 (m, 1H); 7.51 (m,
1H); 8.48 (m, 2H).

3-(3-pyridyl)-1-propyl pyrrolidine-2-
carboxylate

A solution of 3-(3-pyridyl)-1-propyl (2S)-N-(tert-
butyloxycarbonyl)pyrrolidine-2-carboxylate (3.00 g; 9
mmol) in methylene chloride (50 mL) and trifluoroacetic
acid (5 mL) was stirred at room temperature for three
hours. Saturated potassium carbonate was added until the
pH was basic, and the reaction mixture was extracted with
methylene chloride (3x). The combined organic extracts
were dried and concentrated to yield 2.00 g (95%) of the
free amine as a thick oil, ^1H NMR (300 MHz, CDCl_3): δ
1.87-2.20 (m, 6H); 2.79 (m, 2H); 3.03 (m, 2H total); 3.07
(m, 2H); 3.84 (m, 1H); 4.24 (m, 2H); 7.32 (m, 1H); 7.60
(m, 1H); 8.57 (m, 2H).

3-(3-pyridyl)-1-propyl (2S)-1-(2-methylbutyl)-
carbamoylpyrrolidine-2-carboxylate (1)

A solution of 2-methylbutylamine (113 mg; 1.3 mmol)
and triethylamine (132 mg; 1.3 mmol) in methylene
chloride (5 mL) was added to a solution of triphosgene

(128 mg; 0.43 mmol) in methylene chloride (5 mL). The resulting mixture was refluxed for 1 hour and then cooled to room temperature. 3-(3-Pyridyl)-1-propyl (2S)-pyrrolidine-2-carboxylate (300 mg; 1.3 mmol) in 5 mL of methylene chloride was added and the resulting mixture was stirred for 1 hour and then partitioned between water and a 1:1 mixture of ethyl acetate and hexane. The organic phase was dried, concentrated and purified by column chromatography (50% ethyl acetate/hexane) to obtain 250 mg (55%) of the compound of Example 1 (1, Table I) as an oil, ^1H NMR (CDCl_3 , 300 MHz): δ 0.89-0.93 (m, 6H); 1.10-1.20 (m, 1H); 1.27 (s, 1H); 1.36-1.60 (m, 2H); 1.72 (s, 2H); 1.97-2.28 (m, 6H); 2.70-2.75 (m, 2H); 2.92-3.54 (m, 4H); 4.16-4.20 (dt, 2H); 4.45-4.47 (m, 2H); 7.21-7.29 (m, 1H); 7.53-7.56 (dd, 1H); 8.46-8.48 (s, 2H). Anal. Calcd. for $\text{C}_{11}\text{H}_{21}\text{N}_2\text{O}_3 \cdot 0.5 \text{H}_2\text{O}$: C, 64.02; H, 8.48; N, 11.79. Found: C, 63.72; H, 8.42; N, 11.83.

EXAMPLE 2

Synthesis of 3-(3-pyridyl)-1-propyl (2S)-1-[(1',1'-dimethylpropyl)carbamoyl]pyrrolidine-2-carboxylate (2)

Reaction of 3-(3-pyridyl)-1-propyl (2S)-pyrrolidine-2-carboxylate with the isocyanate generated from tert-amylamine and triphosgene, as described for Example 1, provided the compound of Example 2 (2, Table I) in 62% yield, ^1H NMR (CDCl_3 , 300 MHz): δ 0.83 (t, 3H); 1.27 (s,

29

6H); 1.64-1.71 (m, 2H); 1.91-2.02 (m, 7H); 2.66-2.71 (t, 2H); 3.29-3.42 (m, 2H); 4.11-4.15 (t, 3H); 4.37-4.41 (m, 1H). Anal. Calcd. for $C_{19}H_{23}N_3O_3 \cdot 0.5 H_2O$: C, 64.04; H, 8.48; N, 11.79. Found: C, 64.23; H, 8.31; N, 11.30.

5

EXAMPLE 3

Synthesis of 3-(3-pyridyl)-1-propyl (2S)-1-
[(cyclohexyl)thiocarbamoyl]-pyrrolidine-2-carboxylate (3)

A mixture of cyclohexylisothiocyanate (120 mg; 0.9 mmol), 3-(3-pyridyl)-1-propyl (2S)-pyrrolidine-2-carboxylate (200 mg; 0.9 mmol) triethylamine (90 mg; 0.9 mmol) in 20 mL of methylene chloride was stirred for 1 hour and then partitioned between water and a 1:1 mixture of ethyl acetate and hexane. The organic phase was dried, concentrated and purified by column chromatography (50% ethyl acetate/hexane) to obtain 160 mg (47%) of the compound of Example 3 (3, Table I), 1H NMR ($CDCl_3$, 300 MHz): δ 1.16-1.40 (m, 6H); 1.50-1.71 (m, 4H); 1.95-2.08 (m, 7H); 2.70-2.75 (t, 2H); 3.40-3.60 (m, 2H); 4.17-4.26 (m, 2H); 4.95-4.98 (d, 1H); 5.26-5.29 (d, 1H); 7.17-7.25 (m, 1H). Anal. Calcd. for $C_{26}H_{31}N_3O_2S$: C, 63.57; H, 7.78; N, 11.19. Found: C, 63.25; H, 7.80; N, 11.07.

15

20

EXAMPLE 4

25

Synthesis of 3-(3-pyridyl)-1-propyl (2S)-1-
[(cyclohexyl)carbamoyl]-pyrrolidine-2-carboxylate (4)

A mixture of cyclohexylisocyanate (100 mg; 0.9 mmol), 3-(3-pyridyl)-1-propyl (2S)-pyrrolidine-2-carboxylate (200 mg; 0.9 mmol) and triethylamine (90 mg; 0.9 mmol) in 20 mL of methylene chloride was stirred for 1 hour and then partitioned between water and a 1:1 mixture of ethyl acetate and hexane. The organic phase was dried, concentrated and purified by column chromatography (50% ethyl acetate/hexane) to obtain 120 mg (36%) of the compound of Example 4 (4, Table I), ¹H NMR (CDCl₃, 300 MHz): δ 1.10-1.27 (m, 6H); 1.69-1.75 (m, 4H); 1.94-2.03 (m, 4H); 2.67-2.73 (t, 2H); 3.31-3.44 (m, 3H); 4.12-4.16 (m, 2H); 4.39-4.42 (m, 1H); 7.25-7.34 (m, 1H); 7.25-7.55 (dd, 1H); 8.45 (s, 2H). Anal. Calcd. for C₂₀H₂₃N₃O₂ · 0.6 H₂O: C, 64.88; H, 8.22; N, 11.35. Found: C, 64.60; H, 8.18; N, 11.21.

EXAMPLE 5

Synthesis of 3-(3-pyridyl)-1-propyl (2S)-1-[(1-adamantyl)thiocarbonyl]-pyrrolidine-2-carboxylate (5)

A mixture of 1-adamantylisocyanate (250 mg; 0.9 mmol), 3-(3-pyridyl)-1-propyl (2S)-pyrrolidine-2-carboxylate (200 mg; 0.9 mmol) and triethylamine (90 mg; 0.9 mmol) in 20 mL of methylene chloride was stirred for 1 hour and then partitioned between water and a 1:1 mixture of ethyl acetate and hexane. The organic phase was dried, concentrated and purified by column

chromatography (50% ethyl acetate/hexane) to obtain 150
mg (38%) of the compound of Example 4 (4, Table I), ¹H
NMR (CDCl₃, 300 MHz): δ 1.39-1.44 (d, 2H); 1.65 (s, 4H);
1.95-2.07 (m, 8H); 2.07-2.20 (m, 5H); 2.71-2.76 (m, 2H);
3.37-3.45 (m, 1H); 3.50-3.60 (m, 1H); 4.09-4.18 (m, 2H);
4.99-5.21 (d, 1H); 7.21-7.25 (m, 1H). Anal. Calcd. for
C₂₄H₃₃N₃O₂S · 0.4 H₂O: C, 66.30; H, 7.84; N, 9.66. Found:
C, 66.41; H, 7.79; N, 9.50.

As discussed above, the carbamates and ureas used in
the methods of the present invention have an affinity for
the FK506 binding protein, particularly FKBP12. The
inhibition of the prolyl peptidyl *cis-trans* isomerase
activity of FKBP may be measured as an indicator of this
affinity.

K_i Test Procedure

Inhibition of the peptidyl-prolyl isomerase
(rotamase) activity of the inventive compounds can be
evaluated by known methods described in the literature
(Harding, et al., *Nature*, 1989, 341:758-760; Holt et al.
J. Am. Chem. Soc., 115:9923-9938). These values are
obtained as apparent K_i's and are presented in Table II.
The *cis-trans* isomerization of an alanine-proline bond in
a model substrate, N-succinyl-Ala-Ala-Pro-Phe-*p*-
nitroanilide, is monitored spectrophotometrically in a

chymotrypsin-coupled assay, which releases para-nitroanilide from the *trans* form of the substrate. The inhibition of this reaction caused by the addition of different concentrations of inhibitor is determined, and the data is analyzed as a change in first-order rate constant as a function of inhibitor concentration to yield the apparent K_i values.

In a plastic cuvette are added 950 μ L of ice cold assay buffer (25 mM HEPES, pH 7.8, 100 mM NaCl), 10 μ L of FKBP (2.5 mM in 10 mM Tris-Cl pH 7.5, 100 mM NaCl, 1 mM dithiothreitol), 25 μ L of chymotrypsin (50 mg/mL in 1 mM HCl) and 10 μ L of test compound at various concentrations in dimethyl sulfoxide. The reaction is initiated by the addition of 5 μ L of substrate (succinyl-Ala-Phe-Pro-Phe-para-nitroanilide, 5 mg/mL in 2.35 mM LiCl in trifluoroethanol).

The absorbance at 390 nm versus time is monitored for 90 seconds using a spectrophotometer and the rate constants are determined from the absorbance versus time data files.

The data for these experiments for representative compounds are presented in Table II under the column " K_i ".

The neurotrophic effects of the carbamates and ureas used in the methods of the present invention can be demonstrated in cellular biological experiments *in vitro*,


as described below.

Chick Dorsal Root Ganglion

Cultures and Neurite Outgrowth

5 Dorsal root ganglia were dissected from chick embryos of ten day gestation. Whole ganglion explants were cultured on thin layer Matrigel-coated 12 well plates with Liebovitz L15 plus high glucose media supplemented with 2 mM glutamine and 10% fetal calf serum, and also containing 10 μ M cytosine β -D
10 arabinofuranoside (Ara C) at 37°C in an environment containing 5% CO₂. Twenty-four hours later, the DRGs were treated with various immunophilin ligands. Forty-eight hours after drug treatment, the ganglia were
15 visualized under phase contrast or Hoffman Modulation contrast with a Zeiss Axiovert inverted microscope. Photomicrographs of the explants were made, and neurite outgrowth was quantitated. Neurites longer than the DRG diameter were counted as positive, with total number of
20 neurites quantitated per each experimental condition. Three to four DRGs are cultured per well, and each treatment was performed in duplicate.

The data for these experiments for representative
25 compounds are presented in the "ED50" column of Table II.

TABLE IExamples

10

No.	m	Z	n	D	B	R ₁	R ₂
1	1	O	2	3-pyridyl H		2-methylbutyl	H
2	1	O	2	3-pyridyl H		1,1-dimethylpropyl	H
3	1	S	2	3-pyridyl H		cyclohexyl	H
4	1	O	2	3-pyridyl H		cyclohexyl	H
15	5	S	2	3-pyridyl H		1-adamantyl	H

TABLE IIIn Vitro Activity of Example Compounds

20

Example No.	Ki, nM	ED50, nM
1	70	0.065
2	742	1
3	131	0.292
4	1482	n.d.
25	116	0.141

MPTP Model of Parkinson's Disease

The remarkable neurotrophic and neuroregenerative effects of the present inventive compounds were further demonstrated in an animal model of neurodegenerative disease. MPTP lesioning of dopaminergic neurons in mice was used as an animal model of Parkinson's Disease. Four week old male CD1 white mice were dosed i.p. with 30 mg/kg of MPTP for 5 days. Test compounds (4 mg/kg), or vehicle, were administered s.c. along with the MPTP for 5 days, as well as for an additional 5 days following cessation of MPTP treatment. At 18 days following MPTP treatment, the animals were sacrificed and the striata were dissected and perfusion-fixed. Immunostaining was performed on sagittal and coronal brain sections using anti-tyrosine hydroxylase 1 g to quantitate survival and recovery of dopaminergic neurons. In animals treated with MPTP and vehicle, a substantial loss of functional dopaminergic terminals was observed as compared to non-lesioned animals. Lesioned animals receiving test compounds showed a significant recovery of TH-stained dopaminergic neurons. Table III presents quantitation for the recovery of TH-positive dopaminergic neurons in the striatum of animals receiving compounds 1, 2, 5 and 6 in this model.

TABLE IIIIn Vivo Activity of Example Compounds

<u>Example No.</u>	<u>% Recovery of TH</u> <u>Immunostaining, 4 mg/kg</u>
5	<u>S.C.</u>
1	27.47
2	n.d.
3	56.13
4	59.79
10	52.32

All publications and patents identified above are hereby incorporated by reference.


15 The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention and all such modifications are intended to be included within the scope of the following claims.

20

WHAT IS CLAIMED IS:

1. A method of effecting a neuronal activity in an animal, comprising:

5 administering to the animal a neurotrophically effective amount of a compound of formula I:



or a pharmaceutically acceptable salt thereof, wherein:

15 A is CH₂, oxygen, NH or N-(C1-C4 alkyl);

B and D are independently Ar, hydrogen, (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl or alkynyl, (C5-C7)-cycloalkyl substituted (C1-C6)-straight or branched alkyl or (C3-C6)-straight or branched alkenyl or alkynyl, (C5-C7)-cycloalkenyl substituted (C1-C6)-straight or branched alkyl or (C3-C6)-straight or branched alkenyl or alkynyl, Ar-substituted (C1-C6)-straight or branched alkyl, Ar-substituted (C3-C6)-straight or branched alkenyl or alkynyl;

20

25

any one of the CH_2 groups of said alkyl chains may be optionally replaced by a heteroatom selected from the group consisting of O, S, SO, SO_2 , and NR, wherein R is selected from the group consisting of hydrogen, (C1-C4)-straight or branched alkyl, (C3-C4)-straight or branched alkenyl or alkynyl, and (C1-C4) bridging alkyl wherein a bridge is formed between the nitrogen and a carbon atom of said heteroatom-containing chain to form a ring, and wherein said ring is optionally fused to an Ar group;

J is selected from the group consisting of hydrogen, (C1-C6)-straight or branched alkyl, (C3-C6)-straight or branched alkenyl and $-\text{CH}_2\text{Ar}$; K is selected from the group consisting of (C1-C4)-straight or branched alkyl, $-\text{CH}_2\text{Ar}$, and cyclohexylmethyl; or J and K may be taken together to form a 5-7 membered heterocyclic ring which may contain a heteroatom selected from the group consisting of O, S, SO and SO_2 ;

Z is O or S;

Y is O or N, wherein

when Y is O, then R_1 is a lone pair and R_2 is selected from the group consisting of Ar, (C1-C6)-straight or branched alkyl, and (C3-C6)-straight or branched alkenyl or alkynyl; and

when Y is N, then R_1 and R_2 are independently selected from the group consisting of Ar, (C1-C6)-straight or branched alkyl, and (C3-C6)-straight or

branched alkenyl or alkynyl; or R₁ and R₂ are taken together to form a heterocyclic 5-6 membered ring selected from the group consisting of pyrrolidine, imidazolidine, pyrazolidine, piperidine, and piperazine;

5 Ar is a carbocyclic aromatic group selected from the group consisting of phenyl, 1-naphthyl, 2-naphthyl, indenyl, azulenyl, fluorenyl, and anthracenyl; or a heterocyclic aromatic group selected from the group consisting of 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, oxazolyl, 10 thiazolyl, imidazolyl, pyrazolyl, 2-pyrazolinyl, pyrazolidinyl, isoxazolyl, isotriazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, 1,3,4-thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, 1,3,5-trithianyl, indolizinyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furanyl, benzo[b]thio-phenyl, 1H-indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H-quinolizinyl, quinolinyl, 1,2,3,4-tetrahydroquinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, 15 cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, and phenoxazinyl;

20 Ar may contain one or more substituents which are independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, -SO₃H, trifluoromethyl, trifluoromethoxy, (C1-C6)-straight or

branched alkyl, (C2-C6)-straight or branched alkenyl, O-
 [(C1-C6)-straight or branched alkyl], O-[(C3-C4)-straight
 or branched alkenyl], O-benzyl, O-phenyl, 1,2-
 methylenedioxy, -NR₁R₂, carboxyl, N-(C1-C5-straight or
 5 branched alkyl or C3-C5-straight or branched alkenyl)
 carboxamides, N,N-di-(C1-C5-straight or branched alkyl or
 C3-C5-straight or branched alkenyl) carboxamides,
 morpholinyl, piperidinyl, O-X, CH₂-(CH₂)_q-X, O-(CH₂)_q-X,
 (CH₂)_q-O-X, and CH=CH-X;

10 R₁ and R₂ are independently selected from the group
 consisting of (C1-C6)-straight or branched alkyl, (C3-
 C6)-straight or branched alkenyl, hydrogen and benzyl; or
 R₁ and R₂ can be taken together to form a 5-6 membered
 heterocyclic ring;

15 X is selected from the group consisting of 4-
 methoxyphenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrazyl,
 quinolyl, 3,5-dimethylisoxazolyl, isoxazolyl, 2-
 methylthiazolyl, thiazolyl, 2-thienyl, 3-thienyl, and
 pyrimidyl;

20 q is 0-2; and
 n is 0 or 1.

25 2. The method of claim 1, wherein the neuronal
 activity is selected from the group consisting of
 stimulation of damaged neurons, promotion of neuronal
 regeneration, prevention of neurodegeneration and

treatment of neurological disorder.

3. The method of claim 2, wherein the neurological disorder is selected from the group consisting of peripheral neuropathy caused by physical injury or disease state, physical damage to the brain, physical damage to the spinal cord, stroke associated with brain damage, and neurological disorder relating to neurodegeneration.

10

4. The method of claim 3, wherein the neurological disorder relating to neurodegeneration is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, and amyotrophic lateral sclerosis.

15

5. The method of claim 1, wherein, in formula I, J and K are taken together to form a 5-7 membered ring.

6. The method of claim 5, wherein the neuronal activity is selected from the group consisting of stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration and treatment of neurological disorder.

20

7. The method of claim 6, wherein the neurological disorder is selected from the group consisting of

peripheral neuropathy caused by physical injury or
disease state, physical damage to the brain, physical
damage to the spinal cord, stroke associated with brain
damage, and neurological disorder relating to
S neurodegeneration.

8. The method of claim 7, wherein the neurological
disorder relating to neurodegeneration is selected from
the group consisting of Alzheimer's Disease, Parkinson's
10 Disease, and amyotrophic lateral sclerosis.

9. The method of claim 5, wherein, in formula I, at
least one of B and D is independently represented by the
formula $-(CH_2)_r-(X)-(CH_2)_s-Ar$, wherein:

15 r is 1-4;

s is 0-1;

Ar is as defined in claim 1; and

each X is independently selected from the group
consisting of CH_2 , O, S, SO, SO_2 , and NR, wherein R is
20 selected from the group consisting of hydrogen, (C1-C4)-
straight or branched alkyl, (C3-C4)-straight or branched
alkenyl or alkynyl, and (C1-C4) bridging alkyl wherein a
bridge is formed between the nitrogen atom and the Ar
group.

25

10. The method of claim 9, wherein the neuronal

activity is selected from the group consisting of stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration and treatment of neurological disorder.

5

11. The method of claim 10, wherein the neurological disorder is selected from the group consisting of peripheral neuropathy caused by physical injury or disease state, physical damage to the brain, physical damage to the spinal cord, stroke associated with brain damage, and neurological disorder relating to neurodegeneration.

12. The method of claim 11, wherein the neurological disorder relating to neurodegeneration is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, and amyotrophic lateral sclerosis.

13. A method of claim 1, wherein, in formula I:
Ar is selected from the group consisting of phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, indolyl, isoindolyl, quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, and 1,2,3,4-tetrahydroquinolinyl, wherein said Ar may contain one or more substituents which are independently selected from

the group consisting of hydrogen, hydroxyl, nitro, trifluoromethyl, (C1-C6)-straight or branched alkyl, o-[(C1-C6)-straight or branched alkyl], halogen, SO₂R, and NR₂R₁; and

5 R₁ and R₂ are independently selected from the group consisting of (C1-C6)-straight or branched alkyl, (C3-C6)-straight or branched alkenyl, hydrogen and benzyl; or R₁ and R₂ can be taken together to form a 5-6 membered heterocyclic ring.

10

14. The method of claim 13, wherein the neuronal activity is selected from the group consisting of stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration and
15 treatment of neurological disorder.


15. The method of claim 14, wherein the neurological disorder is selected from the group consisting of peripheral neuropathy caused by physical
20 injury or disease state, physical damage to the brain, physical damage to the spinal cord, stroke associated with brain damage, and neurological disorder relating to neurodegeneration.

25 16. The method of claim 15, wherein the neurological disorder relating to neurodegeneration is

selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, and amyotrophic lateral sclerosis.

5 17. A method of effecting a neuronal activity in an animal, comprising:

administering to the animal a neurotrophically effective amount of a compound of formula II or III:



15

or a pharmaceutically acceptable salt thereof, wherein:

Y, R₁ and R₂ are as defined in claim 1, Ar is as defined in claim 4 and w is 1 or 2.

20 18. The method of claim 17, wherein the neuronal activity is selected from the group consisting of stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration and treatment of neurological disorder.


25

19. The method of claim 18, wherein the

neurological disorder is selected from the group consisting of peripheral neuropathy caused by physical injury or disease state, physical damage to the brain, physical damage to the spinal cord, stroke associated with brain damage, and neurological disorder relating to neurodegeneration.

20. The method of claim 19, wherein the neurological disorder relating to neurodegeneration is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, and amyotrophic lateral sclerosis.

21. A method of effecting a neuronal activity in an animal, comprising:
administering to the animal a neurotrophically effective amount of a compound of formula III or IV:



25 or a pharmaceutically acceptable salt thereof, wherein:

Y, R₁ and R₂ are as defined in claim 1, Ar is as defined in claim 4, J is hydrogen, (C1-C6)-straight or branched alkyl or (C3-C6)-straight or branched alkenyl, and w is 1 or 2.

5

22. The method of claim 21, wherein the neuronal activity is selected from the group consisting of stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration and treatment of neurological disorder.

10

23. The method of claim 22, wherein the neurological disorder is selected from the group consisting of peripheral neuropathy caused by physical injury or disease state, physical damage to the brain, physical damage to the spinal cord, stroke associated with brain damage, and neurological disorder relating to neurodegeneration.

15

24. The method of claim 23, wherein the neurological disorder relating to neurodegeneration is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, and amyotrophic lateral sclerosis.

20

AMENDED CLAIMS

[received by the International Bureau on 10 July 1998 (10.07.98);
original claim 1 amended; remaining claims unchanged (2 pages)]

any one of the CH₂ groups of said alkyl chains may
be optionally replaced by a heteroatom selected from
the group consisting of O, S, SO, SO₂, and NR, wherein
R is selected from the group consisting of hydrogen,
5 (C1-C4)-straight or branched alkyl, (C3-C4)-straight or
branched alkenyl or alkynyl, and (C1-C4) bridging alkyl
wherein a bridge is formed between the nitrogen and a
carbon atom of said heteroatom-containing chain to form
a ring, and wherein said ring is optionally fused to an
10 Ar group;

J is selected from the group consisting of
hydrogen, (C1-C6)-straight or branched alkyl, (C3-C6)-
straight or branched alkenyl and -CH₂Ar; K is selected
from the group consisting of (C1-C4)-straight or
15 branched alkyl, -CH₂Ar, and cyclohexylmethyl; or J and
K may be taken together to form a 5-7 membered
heterocyclic ring which may contain a heteroatom
selected from the group consisting of O, S, SO and SO₂;

Z is O or S;

20 Y is O or N, wherein

when Y is O, then R₁ is a lone pair and R₂ is
selected from the group consisting of Ar, (C1-C6)-
straight or branched alkyl, and (C3-C6)-straight or
branched alkenyl or alkynyl; and

25 when Y is N, then R₁ and R₂ are independently
selected from the group consisting of Ar, hydrogen,

cyclohexyl, adamantyl, (C1-C6)-straight or branched
alkyl, and (C3-C6)-straight or

AMENDED SHEET (ARTICLE 19)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/03485

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) : A61K 31/34, 31/535 US CL : 514/212, 227.8, 231.5, 261, 300, 315, 316, 318, 326, 422, 408 According to International Patent Classification (IPC) or to both national classification and IPC														
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/212, 227.8, 231.5, 261, 300, 315, 316, 318, 326, 422, 408 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN-CAS ONLINE														
C. DOCUMENTS CONSIDERED TO BE RELEVANT														
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
A,P	US 5,620,971 A (ARMISTEAD et al) 15 April 1997, see Table 1.	1-24												
A	Database WPIDS on STN, Vertex Pharmaceuticals Inc., WPIDS No. 92-433329, Duffy, J. P., "New alpha-sulphonyl aminocarbonyl derivs. - have affinity for the FK-506 binding protein, are immunosuppressants for treating auto-immune disease, transplant rejection, etc.", abstract, WO 9221313 A2, 12/10/92. See entire abstract.	1-24												
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.														
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*B* earlier document published on or after the international filing date</td> <td>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*A* document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means		*P* document published prior to the international filing date but later than the priority date claimed	
* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
L document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family													
O document referring to an oral disclosure, use, exhibition or other means														
P document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search 28 MARCH 1998		Date of mailing of the international search report 11 MAY 1998												
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer KEITH MACMILLAN Telephone No. (703) 308-1235												